Volume 1.48 | Dec 14

Hematopoiesis News 1.48, December 14, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Leukemia Stem Cell Discovery  ShareThis
Researchers have discovered that leukemic stem cells can be reversed to a pre-leukemic stage by suppressing a protein called beta-catenin found in the blood. They also found that advanced leukemic stem cells that had become resistant to treatment could be ‘re-sensitised’ to treatment by suppressing the same protein. [Press release from King’s College London discussing online prepublication in Cancer Cell]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 


SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @Hema_News



SCIENCE NEWS

Small Molecule May Disarm Enemy of Cancer-Fighting p53
A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53. [Press release from the University of Texas MD Anderson Cancer Center discussing data presented at the 52nd American Society of Hematology Annual Meeting]

Drugs are Safe, Active in Patients Normally Ineligible for Clinical Trial
A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status, researchers reported. [Press release from the University of Texas MD Anderson Cancer Center discussing data presented at the 52nd American Society of Hematology Annual Meeting]

CFCAssayVid_645x110


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Beta-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cells
Here, researchers demonstrated that beta-catenin was activated during development of MLL leukemic stem cells (LSCs). Suppression of beta-catenin reversed LSCs to a pre-LSC-like stage and significantly reduced the growth of human MLL leukemic cells. [Cancer Cell]

Therapy-Induced Selective Loss of Leukemia-Initiating Activity in Murine Adult T Cell Leukemia
In this study, researchers demonstrate that an As2O3 and IFN-alpha combination, known to trigger Tax proteolysis, cures Tax-driven adult T cell leukemia/lymphoma in mice. [J Exp Med]

GABP Controls a Critical Transcription Regulatory Module that Is Essential for Maintenance and Differentiation of Hematopoietic Stem/Progenitor Cells
Here, researchers demonstrate cell-intrinsic, absolute dependence on GA binding protein (GABP)-alpha for maintenance and differentiation of hematopoietic stem/progenitor cells. [Blood]

Deregulation of Aiolos Expression in Chronic Lymphocytic Leukemia is Associated to Epigenetic Modifications
To determine the consequences of Aiolos deregulation in chronic lymphocytic leukemia, researchers analysed the effects of Aiolos overexpression or downregulation on apoptosis. [Blood]

Discovery of a CXCR4 Agonist Pepducin that Mobilizes Bone Marrow Hematopoietic Cells
Researchers prepared and screened a small CXCR4-targeted pepducin library and identified several pepducins with in vitro agonist activity, including ATI-2341, whose peptide sequence derives from the first intracellular loop. ATI-2341 induced CXCR4- and G protein-dependent signaling, receptor internalization, and chemotaxis in CXCR4-expressing cells. [Proc Natl Acad Sci USA]

Biological and Clinical Relevance of Quantitative Global Methylation of Repetitive DNA Sequences in Chronic Lymphocytic Leukemia
Herein, researchers investigated the methylation levels of repetitive DNA elements in chronic lymphocytic leukemia, their correlation with the major cytogenetic and molecular features, and clinical relevance in predicting therapy-free survival. [Epigenetics]

Methylation Markers Identify High Risk Patients in IGHV Mutated Chronic Lymphocytic Leukemia
Here, researchers have studied the potential utility of a panel of methylation markers (CD38, HOXA4 and BTG4) in 118 chronic lymphocytic leukemia patients. [Epigenetics]

Transcriptional and Post-Transcriptional Mechanisms of BAFF-Receptor Dysregulation in Human B Lineage Malignancies
In this study, researchers used primary cells and cell lines to interrogate the mechanisms underlying aberrant BAFF-R expression in precursor B acute lymphoblastic leukemia and mature B chronic lymphocytic leukemia. [Cell Cycle]

The Ubiquitin-Proteasome Pathway Plays Essential Roles in ATRA-Induced Leukemia Cells G0/G1 Phase Arrest and Transition into Granulocytic Differentiation
Here, researchers observed that the ubiquitin-proteasome pathway (UPP) was activated upon all-trans retinoic acid (ATRA) treatment in the human acute myeloid leukemia cell lines, NB4 and HL-60, as represented by the accumulation of ubiquitinated proteins, the up-regulation of ubiquitin mRNA and increased 20S proteasome activity. [Cancer Biol Ther]

CLINICAL RESEARCH

Limited Clinical Relevance of Imaging Techniques in the Follow-Up of Patients with Advanced Chronic Lymphocytic Leukemia: Results of a Meta-Analysis
The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed using the dataset of three GCLLSG phase III trials (CLL4, CLL5 and CLL8) including 1372 patients receiving first line therapy for CLL. [Blood]

A Phase II Trial of the Oral mTOR Inhibitor Everolimus in Relapsed Aggressive Lymphoma
The goal of this trial was to learn the antitumor activity and toxicity of single-agent everolimus in patients with relapsed/refractory aggressive non-Hodgkin’s lymphoma. [Leukemia]

Risk Stratification Using a New Prognostic Score for Patients with Secondary Acute Myeloid Leukemia: Results of the Prospective AML96 Trial
In addition to the known risk factors for acute myeloid leukemia, age and karyotype, researchers identified the absolute platelet count and the Nucleophosmin 1 mutational status at diagnosis as prognostic factors of secondary acute myeloid leukemia patients. [Leukemia]


INDUSTRY NEWS

Watson Confirms Development Agreement with Natco for Generic Revlimid®
Watson Pharmaceuticals, Inc. and Natco Pharma Limited confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. [Watson Pharmaceuticals, Inc. Press Release]

Encouraging Phase II Interim Data for Elotuzumab in Relapsed Multiple Myeloma Presented at 52nd American Society of Hematology Annual Meeting
Abbott and Bristol-Myers Squibb Company announced interim results from the Phase II portion of a Phase Ib/II open-label study which showed a high objective response rate among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone. [Bristol-Myers Squibb Press Release]

Novartis Phase II LBH589 Data Show Substantial Disease Control and Tumor Reduction in Extensively Pretreated Hodgkin Lymphoma Patients
The Novartis oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients who had relapsed or had become refractory after an autologous stem cell transplant, according to new data from a Phase II clinical trial. [Novartis Press Release]

Longer-Term Phase III Data Show Novartis Drug Tasigna® Continues to Surpass Glivec® in Slowing Disease Progression in Patients with Newly Diagnosed CML
Novartis announced 24-month data showing that Tasigna® (nilotinib) continues to surpass Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. [Novartis Press Release]

Onyx Pharmaceuticals Announces Positive Complete Results from Carfilzomib Phase IIb Study
Onyx Pharmaceuticals, Inc. announced positive complete results from the Phase IIb 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. [Onyx Pharmaceuticals, Inc. Press Release]

Single Dose ZEVALIN in First-Ever Phase II Monotherapy Trial for Non-Hodgkin’s Lymphoma Shows Significant and Durable Clinical Responses
Spectrum Pharmaceuticals, Inc. announced independent researchers from leading universities in Germany, Austria, Italy, and Sweden, reported early positive results from the first Phase II clinical trial evaluating treatment-naïve patients with follicular non-Hodgkin’s lymphoma treated with ZEVALIN (ibritumomab tiuxetan) injection for intravenous use as a monotherapy. [Spectrum Pharmaceuticals, Inc. Press Release]


POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


EVENTS (Listed by Date)

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada

Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States

Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States

Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States

Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France

World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.


Have we missed an important article or publication in Hematopoiesis News? Click here to submit!




Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us